NovoCure (NVCR) Asset Writedowns and Impairment (2014 - 2026)

NovoCure (NVCR) has reported Asset Writedowns and Impairment for 13 consecutive years, with $738000.0 the latest figure, recorded in Q2 2026.

• Quarterly Asset Writedowns and Impairment rose 74.06% year-over-year to $738000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.6 million (up 3.02% YoY) and the FY2025 annual result came in at $4.9 million, up 318.55% from the prior year.
• Asset Writedowns and Impairment grew to $738000.0 in Q2 2026 per NVCR's latest filing, from $712000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for NVCR reached as high as $2.3 million in Q1 2025 and fell as low as $112000.0 in Q3 2023.
• A 5-year average of $494888.9 and a median of $223000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment plunged 73.02% — and 2025, when it surged 1065.46%.
• Year by year, Asset Writedowns and Impairment stood at $441000.0 in 2022, then plunged by 73.02% to $119000.0 in 2023, then jumped by 215.13% to $375000.0 in 2024, then jumped by 416.27% to $1.9 million in 2025, then tumbled by 61.88% to $738000.0 in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $738000.0, $712000.0, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.